Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis
Adriano H Moffa,Donel Martin,Angelo Alonzo,Djamila Bennabi,Daniel M Blumberger,Isabela M Benseñor,Zafiris Daskalakis,Felipe Fregni,Emmanuel Haffen,Sarah H Lisanby,Frank Padberg,Ulrich Palm,Lais B Razza,Bernardo Sampaio-Jr,Colleen Loo,Andre R Brunoni,Adriano H. Moffa,Daniel M. Blumberger,Isabela M. Benseñor,Sarah H. Lisanby,Lais B. Razza,Andre R. Brunoni
DOI: https://doi.org/10.1016/j.pnpbp.2019.109836
2020-04-01
Abstract:We evaluated the efficacy and acceptability of transcranial direct current stimulation (tDCS) for treating acute depressive episodes using individual patient data that provide more precise estimates than aggregate data meta-analysis. A systematic review of placebo-controlled trials on tDCS as only intervention was conducted until December-2018. Data from each study was collated to estimate odds ratio (OR) and number needed to treat (NNT) of response and remission, and depression improvement. Endpoints were pre-determined. Nine eligible studies (572 participants), presenting moderate/high certainty of evidence, were included. Active tDCS was significantly superior to sham for response (30.9% vs. 18.9% respectively; OR = 1.96, 95%CI [1.30–2.95], NNT = 9), remission (19.9% vs. 11.7%, OR = 1.94 [1.19–3.16], NNT = 13) and depression improvement (effect size of β = 0.31, [0.15–0.47]). Moreover, continuous clinical improvement was observed even after the end of acute tDCS treatment. There were no differences in all-cause discontinuation rates and no predictors of response were identified. To conclude, active tDCS was statistically superior to sham in all outcomes, although its clinical effects were moderate.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology